Loading...
XLON
CRW
Market cap1.05bUSD
Jul 11, Last price  
2,220.00GBP
1D
-1.33%
1Q
46.05%
Jan 2017
67.55%
IPO
1,457.89%
Name

Craneware PLC

Chart & Performance

D1W1MN
P/E
8,961.72
P/S
554.13
EPS
0.33
Div Yield, %
1.18%
Shrs. gr., 5y
5.31%
Rev. gr., 5y
21.53%
Revenues
189m
+8.76%
5,834,00013,178,34515,110,70318,676,00022,993,00028,397,00038,124,00041,067,00041,452,00042,574,00044,817,00049,846,00057,796,00067,067,00071,401,00071,492,00075,578,000165,544,000174,018,000189,268,000
Net income
12m
+26.77%
1,027,0002,144,3671,216,2423,289,0004,448,0005,525,0006,015,0008,893,0008,296,0008,610,0009,388,00010,575,00013,525,00015,797,00014,985,00016,836,00012,905,0009,409,0009,232,00011,703,000
CFO
42m
-57.61%
1,827,0004,004,296987,4443,492,0007,176,0006,718,0008,494,0009,286,0006,617,0008,109,00019,582,00015,422,00017,852,00029,988,00013,463,00020,670,00023,537,00026,964,00098,748,00041,862,000
Dividend
Nov 28, 202416 GBP/sh
Earnings
Sep 01, 2025

Profile

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Toolkit, an automated software-as-a-service (SaaS) chargemaster management solution for capturing optimal legitimate reimbursement for providers; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Reference Plus, a SaaS solution to perform chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; integration for chargemaster management, a software that automatically uploads chargemaster changes to the patient billing system for accurate billing; Trisus Pricing Analyzer, a SaaS solution that simplifies the price modelling process; and Online Reference Toolkit and supplies assistant solutions. It also offers InSight Medical Necessity, a SaaS solution that provides medical necessity validation for the United States payors and advance beneficiary notice creation; Trisus Claims Informatics, a software that automates claim and coding reviews; and InSight Audit, a web-based audit management application for healthcare organizations to manage government and commercial audits. In addition, the company provides Trisus Healthcare Intelligence, a cost analytics and resource efficiency platform; trisus pricing transparency; InSight Denials to analyze, track, trend, and report on denial data; and appeals services. Further, it offers customer success management and consulting services; professional services; and sales and marketing, and product and software development services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
IPO date
Sep 13, 2007
Employees
724
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
189,268
8.76%
174,018
5.12%
Cost of revenue
35,133
32,334
Unusual Expense (Income)
NOPBT
154,135
141,684
NOPBT Margin
81.44%
81.42%
Operating Taxes
4,044
3,853
Tax Rate
2.62%
2.72%
NOPAT
150,091
137,831
Net income
11,703
26.77%
9,232
-1.88%
Dividends
(12,798)
(12,119)
Dividend yield
1.57%
2.51%
Proceeds from repurchase of equity
(3,072)
(3,856)
BB yield
0.38%
0.80%
Debt
Debt current
8,952
9,389
Long-term debt
35,970
80,958
Deferred revenue
958
2,875
Other long-term liabilities
34,149
243
Net debt
10,333
11,810
Cash flow
Cash from operating activities
41,862
98,748
CAPEX
(1,191)
(15,551)
Cash from investing activities
(15,814)
(15,337)
Cash from financing activities
(69,996)
(53,282)
FCF
188,238
142,215
Balance
Cash
34,589
78,537
Long term investments
Excess cash
25,126
69,836
Stockholders' equity
235,880
368,385
Invested Capital
379,678
345,248
ROIC
41.41%
36.61%
ROCE
38.17%
31.04%
EV
Common stock shares outstanding
35,292
35,435
Price
23.10
69.23%
13.65
-25.82%
Market cap
815,245
68.55%
483,688
-25.90%
EV
825,578
629,509
EBITDA
187,518
173,846
EV/EBITDA
4.40
3.62
Interest
5,130
6,357
Interest/NOPBT
3.33%
4.49%